{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Modgil S"],"funding":["Abraham J. and Phyllis Katz Foundation","Research to Prevent Blindness","U.S. Army Medical Research and Development Command","National Institutes of Health"],"pagination":["e0320231"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12478906"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(9)"],"pubmed_abstract":["Brain-derived neurotrophic factor (BDNF) signaling through the tropomyosin-related kinase B (TrkB) receptor promotes neuronal growth and survival following an injury. However, its short half-life and pleiotropic effects limit the clinical use of BDNF as a therapy in neurodegenerative disorders. Identification of novel and selective TrkB activators may ameliorate the damage caused to retinal neurons during eye-related injuries and may reduce adverse visual outcomes associated with visual trauma. We previously described a small molecule, N-[2-(5-hydroxy-1H-indol-3-yl) ethyl]-2-oxopiperidine-3-carboxamide (HIOC), that activates TrkB and reduces the decline in visual function in a mouse model of ocular trauma. Using the lead optimization approach, we subsequently synthesized a fluoropyridine a"],"journal":["PloS one"],"pubmed_title":["Long-term functional rescue of trauma-induced vision loss by a novel, small molecule TrkB modulator."],"pmcid":["PMC12478906"],"funding_grant_id":["N/A","Challenge Grant","W81XWH-18-1-0700","P30EY06360"],"pubmed_authors":["McDonald FE","Iuvone PM","Modgil S","Grossniklaus HE","Walker CL","Chrenek MA"],"additional_accession":[]},"is_claimable":false,"name":"Long-term functional rescue of trauma-induced vision loss by a novel, small molecule TrkB modulator.","description":"Brain-derived neurotrophic factor (BDNF) signaling through the tropomyosin-related kinase B (TrkB) receptor promotes neuronal growth and survival following an injury. However, its short half-life and pleiotropic effects limit the clinical use of BDNF as a therapy in neurodegenerative disorders. Identification of novel and selective TrkB activators may ameliorate the damage caused to retinal neurons during eye-related injuries and may reduce adverse visual outcomes associated with visual trauma. We previously described a small molecule, N-[2-(5-hydroxy-1H-indol-3-yl) ethyl]-2-oxopiperidine-3-carboxamide (HIOC), that activates TrkB and reduces the decline in visual function in a mouse model of ocular trauma. Using the lead optimization approach, we subsequently synthesized a fluoropyridine a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-04T05:09:23.858Z","creation":"2026-05-05T03:12:45.832Z"},"accession":"S-EPMC12478906","cross_references":{"pubmed":["41021607"],"doi":["10.1371/journal.pone.0320231"]}}